These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9433698)

  • 1. Predictive value of several signs of infection as surrogate markers for mortality in a neutropenic guinea pig model of Pseudomonas aeruginosa sepsis.
    Louie A; Liu W; Liu QF; Sucke AC; Miller DA; Battles A; Miller MH
    Lab Anim Sci; 1997 Dec; 47(6):617-23. PubMed ID: 9433698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of surrogate markers of impending death in the galactosamine-sensitized murine model of bacterial endotoxemia.
    Krarup A; Chattopadhyay P; Bhattacharjee AK; Burge JR; Ruble GR
    Lab Anim Sci; 1999 Oct; 49(5):545-50. PubMed ID: 10551457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental Pseudomonas aeruginosa sepsis: absence of synergy between ticarcillin and tobramycin.
    Chusid MJ; Davis SD; Sarff LD
    J Lab Clin Med; 1983 Mar; 101(3):441-9. PubMed ID: 6402553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics.
    Navas D; Caillon J; Gras-Le Guen C; Jacqueline C; Kergueris MF; Bugnon D; Potel G
    J Antimicrob Chemother; 2004 Oct; 54(4):767-71. PubMed ID: 15317741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing.
    Tam VH; Ledesma KR; Schilling AN; Lim TP; Yuan Z; Ghose R; Lewis RE
    Diagn Microbiol Infect Dis; 2009 Aug; 64(4):427-33. PubMed ID: 19631096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of intravitreal ceftazidime, imipenem, and amikacin in a swine model of posttraumatic Pseudomonas aeruginosa endophthalmitis.
    Ng EW; D'Amico DT
    Retina; 1997; 17(5):464-5. PubMed ID: 9355203
    [No Abstract]   [Full Text] [Related]  

  • 8. The establishment of a Pseudomonas aeruginosa-infected burn-wound sepsis model and the effect of imipenem treatment.
    Barnea Y; Carmeli Y; Kuzmenko B; Gur E; Hammer-Munz O; Navon-Venezia S
    Ann Plast Surg; 2006 Jun; 56(6):674-9. PubMed ID: 16721084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Morphological study of the organs and tissues of mice infected after a burn with a Pseudomonas aeruginosa strain and treated with a Pseudomonas aeruginosa polyvalent corpuscular vaccine and tobramycin].
    Moroz AF; Kharitonova AM; Chanturiia TsK
    Antibiotiki; 1983 May; 28(5):341-5. PubMed ID: 6410985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.
    Buijs J; Dofferhoff AS; Mouton JW; van der Meer JW
    J Antimicrob Chemother; 2007 May; 59(5):926-33. PubMed ID: 17395686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.
    Babalola CP; Nightingale CH; Nicolau DP
    J Antimicrob Chemother; 2004 Jun; 53(6):1098-100. PubMed ID: 15128727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adjunctive treatment with gamma interferon against Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.
    Babalola CP; Nightingale CH; Nicolau DP
    Int J Antimicrob Agents; 2004 Sep; 24(3):219-25. PubMed ID: 15325424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN; Micek ST; Reichley RM; Ritchie DJ
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential therapeutic role of histatin derivative P-113d in experimental rat models of Pseudomonas aeruginosa sepsis.
    Cirioni O; Giacometti A; Ghiselli R; Orlando F; Kamysz W; D'Amato G; Mocchegiani F; Lukasiak J; Silvestri C; Saba V; Scalise G
    J Infect Dis; 2004 Jul; 190(2):356-64. PubMed ID: 15216473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis.
    McCormick C; Caballero A; Tang A; Balzli C; Song J; O'Callaghan R
    Curr Med Res Opin; 2008 Jun; 24(6):1569-75. PubMed ID: 18423106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS; Paladino JA; Schentag JJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis.
    Cross AS; Opal SM; Warren HS; Palardy JE; Glaser K; Parejo NA; Bhattacharjee AK
    J Infect Dis; 2001 Apr; 183(7):1079-86. PubMed ID: 11237833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.